Q-omics provides the consensus-scored KIAA1549L profile across patient tissues and cancer cell-line models. KIAA1549L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, KIAA1549L is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, KIAA1549L RNA expression shows 14,934 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight STAD, KIRC, and LIHC as cancer lineages where KIAA1549L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1549L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1549L survival associations across molecular data types. KIAA1549L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1549L RNA expression–survival associations across cancer types. High KIAA1549L expression shows unfavorable associations in STAD, MESO, LUAD and UCEC, but favorable associations in UVM and LGG. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for KIAA1549L RNA expression.
This table summarizes KIAA1549L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIAA1549L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1549L shows lower tumor expression in KIRC and KIRP and higher tumor expression in HNSC, LUSC, COAD and LUAD. The KIRC box plot shows higher KIAA1549L RNA expression in normal versus tumor tissue (log2 FC = −1.131, t-test p < 0.001).
This table shows molecular features associated with KIAA1549L in patient tissues and cancer cell lines. In patient samples, KIAA1549L shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1549L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
